Earlier, we ran a story about proteasome inhibitors. But there is much to say about this critical class of drugs used to treat myeloma. To read that article, click here.
As we know, there are many classes of drugs used alone and in combinations to treat multiple myeloma. One such drug class is the “proteasome inhibitor.”
Proteasome inhibitor drugs
The myeloma drugs in the proteasome inhibitor class are bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro).
How they work
In 2003, the FDA approved a new type of drug called a proteasome inhibitor, for multiple myeloma. It works by blocking the activity of the proteasome, a complex of enzymes found in cells that normally regulates the removal of defective proteins. Inhibiting proteasome function leads to the accumulation of defective proteins, which can trigger cell death. Cancerous cells such as myeloma cells seem to be more sensitive than normal cells to this effect, although some healthy cells can be harmed.
According to Blood…
Proteasome inhibition has emerged as an important therapeutic strategy in myeloma. Since the publication of the first phase 1 trials of bortezomib 10 years ago, this first-in-class proteasome inhibitor has contributed substantially to the observed improvement in survival in myeloma patients over the past decade. Although first approved as a single agent in the relapsed setting, bortezomib is now predominantly used in combination regimens. Furthermore, the standard twice-weekly schedule may be replaced by weekly infusion, especially when bortezomib is used as part of combination regimens in frontline therapy. Indeed, bortezomib is an established component of induction therapy for patients eligible or ineligible for auto stem cell transplantation. Bortezomib has also been incorporated into conditioning regimens before autologous stem cell transplantation, as well as into post-ASCT consolidation therapy, and in the maintenance setting.
In addition, a new route of bortezomib administration, subcutaneous infusion [is available]. Recently, several new agents [in this class of drug] have been introduced into the clinic in patients with relapsed/refractory myeloma [with]positive results.
Bortezomib (Velcade) – First out the gate
Bortezomib was the first proteasome inhibitor approved to treat patients who had already been treated with two other types of chemotherapy and whose cancer has still progressed after the most recent therapy. A Phase I trial in 2000 at the University of North Carolina by Robert Z. Orlowski, MD, PhD focused on hematological malignancies and it was this trial that demonstrated that bortezomib was active in multiple myeloma.Then, in 2008, partly as a result of clinical trials led by by UNC and Memorial Sloan Kettering investigators, bortezomib was approved for use against multiple myeloma in the initial phase of treatment, as it was shown to be very effective in these cases. (from Sloan-Kettering)
Bortezomib is injected into a vein through an IV or as an injection, generally given in the stomach. It is almost always dispensed by your doctor or in the hospital. Taking this drug can lower blood cells that help fight infections and help with blood clotting. Your blood will be tested often while taking this medication and treatment can be delayed as a result.
Some common side effects are: neuropathy; loss of appetite, nausea, vomiting; diarrhea, constipation, bloating; fever, chills, cold or flu symptoms; pale skin, easy bruising or bleeding; rash; and fatigue
In January 2016, carfilzomib (Kyprolis) was approved by the FDA. The drug is given via injection in combination with dex or with lenalidomide plus dex for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. The FDA also approved Kyprolis as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
The most common side-effects are: back or joint pain; constipation; diarrhea; dizziness; headache; loss of appetite; nausea; tiredness; trouble sleeping; vomiting; and weakness.
In November 2015, Ninlaro was approved by the FDA. It is generally used with lenalidomide (Revlimid)) and dex in patients who have received at least one prior treatment for their multiple myeloma. This is the first oral proteasome inhibitor, which makes it far easier to take.
The most common side effects of Ninlaro are diarrhea; constipation; low blood platelet count (thrombocytopenia); peripheral neuropathy (numbness and pain from nerve damage, usually in the hands and feet); nausea, peripheral edema (fluid under the skin causing swelling); vomiting and back pain.
What’s coming up?